<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BROMFENAC - bromfenac sodium solution/ drops </strong><br>Apotex Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Bromfenac Ophthalmic Solution, 0.09% safely and effectively. See full prescribing information for Bromfenac Ophthalmic Solution, 0.09%.<br><br>Bromfenac Ophthalmic Solution, 0.09% <br>Initial U.S. Approval: 1997</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Bromfenac Ophthalmic Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction <span class="Bold"><a href="#i4i_indications_id_abf2bf44-cca0-404f-8605-94db94bfe480">(1)</a></span>.  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One drop should be applied to the affected eye two times daily beginning 24 hours after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery and continued through the first 2 weeks of the post-operative period <span class="Bold"><a href="#i4i_section_id_f0ccad64-59b2-4809-bc95-9c695ceba497">(2.1)</a>.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Topical ophthalmic solution: bromfenac 0.09% <span class="Bold"><a href="#i4i_dosage_form_strength_id_996da360-828e-4142-b4f2-2177c9ee34e2">(3)</a>.</span> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None <a href="#i4i_contraindications_id_10bb991c-7c2e-44b7-abbe-688e08d5720d">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> <span class="Bold"><a href="#i4i_section_id_80219bb1-5467-4706-b6a4-5681fdf88f94">(5.1)</a></span>
</li>
<li>Slow or Delayed Healing <span class="Bold"><a href="#i4i_section_id_51555dfc-f930-4e24-a3f8-4a1bf36c79ac">(5.2)</a></span>
</li>
<li>Potential for cross-sensitivity <span class="Bold"><a href="#i4i_section_id_9e7e0c19-9222-478e-aa13-455184816df8">(5.3)</a></span>
</li>
<li>Increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues <span class="Bold"><a href="#i4i_section_id_f70ac7bf-d093-4502-96a2-7ae7555ff7af">(5.4)</a></span>
</li>
<li>Corneal effects including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> <span class="Bold"><a href="#i4i_section_id_5f8fbb2e-9722-4148-b9f1-ed23ee02af51">(5.5)</a></span>
</li>
<li>Contact Lens Wear <span class="Bold"><a href="#i4i_section_id_afd53186-13ef-4ee2-b29a-8d1bebec5440">(5.6)</a></span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions in 2 to 7% of patients were abnormal sensation in eye, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span> and <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> (including burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) <span class="Bold"><a href="#i4i_section_id_5036f3e8-69c6-4be5-939e-ea22e20441b2">(6.1)</a></span>.<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-667-4708, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use with Other Topical Ophthalmic Medications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Slow or Delayed Healing</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Cross-Sensitivity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Slowed or Delayed Healing</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Concomitant Use of Contact Lenses</a></h2>
<h2><a href="#section-13.4" class="toc">17.4 Concomitant Topical Ocular Therapy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_abf2bf44-cca0-404f-8605-94db94bfe480"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Bromfenac Ophthalmic Solution, 0.09% is indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f07f219a-ca6d-488b-83fa-b2ea642cbc58"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0ccad64-59b2-4809-bc95-9c695ceba497"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">One drop of bromfenac ophthalmic solution should be applied to the affected eye two times daily beginning 24 hours after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery and continuing through the first 2 weeks of the postoperative period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28b3bfb0-48d2-4473-a78d-ef8c1442b5d7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use with Other Topical Ophthalmic Medications</h2>
<p class="First">Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_996da360-828e-4142-b4f2-2177c9ee34e2"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Topical ophthalmic solution: bromfenac 0.09%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_10bb991c-7c2e-44b7-abbe-688e08d5720d"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_a76984fc-c00a-45d0-993c-435dfb84e8b9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80219bb1-5467-4706-b6a4-5681fdf88f94"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51555dfc-f930-4e24-a3f8-4a1bf36c79ac"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Slow or Delayed Healing</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e7e0c19-9222-478e-aa13-455184816df8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Cross-Sensitivity</h2>
<p class="First">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f70ac7bf-d093-4502-96a2-7ae7555ff7af"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></h2>
<p class="First">With some NSAIDs, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery. </p>
<p>It is recommended that bromfenac ophthalmic solution be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f8fbb2e-9722-4148-b9f1-ed23ee02af51"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</h2>
<p class="First">Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.</p>
<p>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</p>
<p>Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_afd53186-13ef-4ee2-b29a-8d1bebec5440"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Contact Lens Wear</h2>
<p class="First">Bromfenac ophthalmic solution should not be administered while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_3994ab5f-c6d4-423d-8c8b-878cd8fd5ada"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5036f3e8-69c6-4be5-939e-ea22e20441b2"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most commonly reported adverse reactions reported following use of bromfenac after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery include: abnormal sensation in eye, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> (including burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">eye redness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>. These events were reported in 2 to 7% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94088857-3d9e-4c63-b479-8cbe51355c7c"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following reactions have been identified during post-marketing use of bromfenac ophthalmic solution, 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution, 0.09% or a combination of these factors, include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, and epithelial breakdown. [<span class="Italics">see Warnings and Precautions </span><span class="Italics"><a href="#i4i_section_id_5f8fbb2e-9722-4148-b9f1-ed23ee02af51">(5.5)</a></span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_7b101aaf-ab48-4878-83ef-5d8573eee5f1"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6a1dce52-34e0-4879-8b1d-395ce52f207f"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p><span class="Bold"></span><span class="Bold Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies with bromfenac ophthalmic solution in pregnant women. No malformations were observed in reproduction studies in rats and rabbits with oral doses of bromfenac at exposures up to 150 times (rats) and 90 times (rabbits) the predicted human systemic exposure; however, both embryolethality and maternal toxicity were observed at the highest dose exposures. The systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans, following ocular administration [<span class="Italics"><a href="#i4i_pharmacokinetics_id_3635a265-b335-4733-81d9-55efa16bd0bf">see Clinical Pharmacology (12.3)</a></span>]. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold"></span><span class="Bold Italics">Clinical Considerations</span></p>
<p>Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Measurable maternal and fetal plasma drug levels are available with oral and injectable routes of NSAID administration. The maternal plasma level of bromfenac following ocular administration is unknown [<span class="Italics"><a href="#i4i_pharmacokinetics_id_3635a265-b335-4733-81d9-55efa16bd0bf">see Clinical Pharmacology (12.3)</a></span>]. </p>
<p><span class="Bold Italics">Animal Data</span></p>
<p> Reproduction studies performed in rats at oral doses of bromfenac up to 0.9 mg/kg/day (systemic exposure 90 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and rabbits at oral doses up to 7.5 mg/kg/day (150 times the predicted human systemic exposure) produced no drug-related malformations in reproduction studies. However, embryo-fetal lethality and maternal toxicity were produced in rats and rabbits at 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human exposure), and caused dystocia, increased neonatal mortality, and reduced postnatal growth at 0.9 mg/kg/day. </p>
<p></p>
<p><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_51a611e7-8029-463e-b236-4885533efa84"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if bromfenac is present in human milk. The systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans, following ocular administration [<span class="Italics"><a href="#i4i_pharmacokinetics_id_3635a265-b335-4733-81d9-55efa16bd0bf">see Clinical Pharmacology (12.3)</a></span>]. Based on the low level of systemic exposure, it is unlikely that bromfenac would be detected in human milk using available assays. Caution should be exercised when bromfenac ophthalmic solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ccf4c0d0-cfd2-4252-bd35-d343122c0e46"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy in pediatric patients below the age of 18 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_9abde8ff-db2a-458a-86d3-50e2ee725744"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is no evidence that the efficacy or safety profiles for bromfenac ophthalmic solution differ in patients 65 years of age and older compared to younger adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1f6e9905-a7b3-4ed1-89f7-09f9ee55d41a"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Bromfenac Ophthalmic Solution, 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of Bromfenac Ophthalmic Solution  contains 1.035 mg bromfenac sodium sesquihydrate (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodium sesquihydrate is designated chemically as sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C<span class="Sub">15</span>H<span class="Sub">11</span>BrNNaO<span class="Sub">3</span>• <span class="Sup">3</span>/<span class="Sub">2</span> H<span class="Sub">2</span>O. The structural structure for bromfenac sodium is:</p>
<div class="Figure"><img alt="chemical structure " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3296f72b-62ba-d417-132b-30c4a6166609&amp;name=chemical-structure.jpg"></div>
<p>Bromfenac sodium sesquihydrate is a yellow or orange yellow crystalline powder. The molecular weight of bromfenac sodium sesquihydrate is 383.17. Bromfenac Ophthalmic Solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of Bromfenac Ophthalmic Solution is approximately 300 mOsmol/kg.</p>
<p> Each mL of Bromfenac Ophthalmic Solution contains:<span class="Bold"><br></span></p>
<p>Active: bromfenac sodium sesquihydrate 0.1035% equivalent to 0.9 mg bromfenac free acid<br><span class="Bold"></span></p>
<p>Preservative: benzalkonium chloride (0.05 mg/mL)<br><span class="Bold"></span></p>
<p>Inactives: boric acid, edetate disodium dihydrate, polysorbate 80, povidone, sodium borate, sodium sulfite anhydrous, sodium hydroxide to adjust pH and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5e10512a-46ef-426a-b187-7d106f950282"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_1a88857e-5f2c-4bb9-80b5-3012252304a9"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.  </p>
<p>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3635a265-b335-4733-81d9-55efa16bd0bf"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The plasma concentration of bromfenac following ocular administration of 0.09% bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.09 mg) twice a day and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_76291a18-356e-4ef7-ad77-78d5ffcf3d31"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d183779d-bb9d-470d-9030-82f3326e712e"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.</p>
<p>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_f3c5f80e-7472-42e3-996d-04d97c7afbef"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9db7596e-c3b4-4db3-9510-8bb61003ee0a"></a><a name="section-11.1"></a><p></p>
<h2>14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></h2>
<p class="First">Clinical efficacy was evaluated in two randomized, double-masked, vehicle-controlled U.S. trials in which subjects with a summed ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> score ≥3 after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery were assigned to bromfenac ophthalmic solution or vehicle in a 2:1 ratio following surgery. One drop of bromfenac ophthalmic solution or vehicle was self-instilled in the study eye twice a day for 14 days, beginning the day after surgery. The primary endpoint was reduction of ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (to trace <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or clearing) assessed 14 days post-surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies a significant effect of bromfenac ophthalmic solution on ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery was demonstrated (62-66% vs. 40-48%).</p>
<p>An additional efficacy endpoint was the time required for resolution of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in subjects who reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Overall, only 20% of the patients undergoing <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery in these trials had <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the first day after surgery. In these patients, the bromfenac ophthalmic solution group demonstrated a statistically significant difference in median time to resolution of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> of 2 days compared to 4 days for patients receiving vehicle.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8755d3cf-b962-4070-8be3-e4ec20d8b2c5"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Bromfenac Ophthalmic Solution, 0.09% is supplied in a white opaque LDPE ophthalmic bottle with white translucent LDPE ophthalmic dropper and grey opaque HDPE ophthalmic cap with sealing tape as follows: :</p>
<p>2.5 mL in 5 mL bottle - NDC 60505-0596-4 </p>
<p>5 mL in 5 mL bottle - NDC 60505-0596-1 </p>
<p><span class="Bold">STORAGE</span></p>
<p>Store at 20° - 25°C (68° - 77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ae826948-8cb2-46d3-bb12-5cce51097ef9"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7548a09-4137-4287-aad6-d787ac5e6cbc"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Slowed or Delayed Healing</h2>
<p class="First">Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c07da7f-ec00-4d91-89ff-279f4909802c"></a><a name="section-13.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</h2>
<p class="First">Advise patients not to touch dropper tip to any surface, as this may contaminate the contents.</p>
<p>Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8fb3c91-c5cb-469e-8774-3d52f3468618"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Concomitant Use of Contact Lenses</h2>
<p class="First">Advise patients that contact lenses should not be worn during the use of this product. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5f0d449-f149-4123-aacc-ae89abfc93ab"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Concomitant Topical Ocular Therapy</h2>
<p class="First">Advise patients that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.</p>
<p><span class="Bold"></span></p>
<table frame="void" rules="none" width="45%">
<colgroup width="25%"></colgroup>
<colgroup width="20%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td>Manufactured by:</td>
<td>Manufactured for:</td>
</tr>
<tr>
<td>Apotex Inc.</td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Toronto, Ontario</td>
<td>Weston, Florida</td>
</tr>
<tr>
<td>Canada M9L 1T9</td>
<td>33326</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td>286446</td>
<td>February 2014</td>
</tr>
</tbody>
</table>
<p></p>
<p></p>
<p></p>
<p><span class="Bold"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0004ac09-b644-41ce-a0c6-835b2f3cc319"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Bottle Label </p>
<p>NDC 60505-0596-1</p>
<p>Bromfenac Ophthalmic Solution, 0.09%</p>
<p>5 mL</p>
<p>Rx Only </p>
<p><img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3296f72b-62ba-d417-132b-30c4a6166609&amp;name=bottle-5ml.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_17ba14cd-7bdf-e471-de7e-c31170c8b0b1"></a><a name="section-15"></a><p></p>
<h1> Principal Display Panel</h1>
<p class="First">Carton Label </p>
<p>NDC 60505-0596-1</p>
<p>Bromfenac Ophthalmic Solution, 0.09%</p>
<p>5 mL</p>
<p>Rx Only </p>
<p><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3296f72b-62ba-d417-132b-30c4a6166609&amp;name=carton-5ml.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BROMFENAC  		
					</strong><br><span class="contentTableReg">bromfenac solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0596</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BROMFENAC SODIUM</strong> (BROMFENAC) </td>
<td class="formItem">BROMFENAC</td>
<td class="formItem">0.9 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BORATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM SULFITE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-0596-4</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-0596-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202435</td>
<td class="formItem">06/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Apotex Corp
							(845263701)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Apotex Inc. (209429182)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Apotex Inc.</td>
<td class="formItem"></td>
<td class="formItem">255092496</td>
<td class="formItem">analysis(60505-0596), manufacture(60505-0596)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b4eb0f62-5919-1b2a-7af7-d641759f0ac7</div>
<div>Set id: 3296f72b-62ba-d417-132b-30c4a6166609</div>
<div>Version: 1</div>
<div>Effective Time: 20140210</div>
</div>
</div> <div class="DistributorName">Apotex Corp</div></p>
</body></html>
